Company profile
ALLOGENE THERAPEUTICS, INC.
NASDAQ:ALLOBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NENDOCABTAGENE ONOGEDLEUCEL | phase1 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07085104 | phase1 | recruiting | 2025-11-13 | 2028-02-01 | Allogene Therapeutics | A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease |
| NCT06500273 | phase2 | recruiting | 2024-06-18 | 2027-12-01 | Allogene Therapeutics | Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL |
| NCT05714345 | phase2 | terminated | 2023-11-01 | 2024-02-20 | Allogene Therapeutics | Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy |
| NCT04696731 | phase1 | active_not_recruiting | 2021-02-24 | 2030-01-01 | Allogene Therapeutics | Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma |
| NCT03939026 | phase1 | completed | 2019-05-01 | 2021-10-23 | Allogene Therapeutics | Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma |
FDA applications (0)
No records yet.